USRE49517EActiveUtility
Pyrazoles

Assignee: JANSSEN PHARMACEUTICALS INCPriority: Aug 15, 2014Filed: Aug 14, 2015Granted: May 2, 2023
Est. expiryAug 15, 2034(~8.1 yrs left)· nominal 20-yr term from priority
Inventors:Rudolf Schindler Hans-Joachim Lankau Norbert Höfgen Christian Grunwald Ute Egerland Barbara Langen Rita Dost Thorsten Hage Simon Edward Ward
A61P 25/24A61P 25/14A61P 25/08A61P 25/30A61P 25/04C07D 403/06A61P 25/16A61P 17/02C07D 231/12A61P 31/00A61P 9/10A61P 43/00A61P 21/00A61P 25/18A61K 31/4155A61K 31/03A61P 3/10A61P 25/28A61P 25/00A61P 29/00
PatentIndex Score
Cited by
123
References
Claims
Abstract

The invention relates to pyrazole derivatives which are NMDA NR2B receptor inhibitors, useful in treating central nervous system diseases.
Claims

exact text as granted — not AI-modified
The invention claimed is: 
     
       1. A compound of Formula (I): 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt, solvate, polymorph, or N-oxide thereof; wherein:
 n is 1 or 2, 
 Het is selected from: 
 
       
         
           
           
               
               
           
         
       
       wherein
 R 1  and R 2  are each independently selected from hydrogen; a halogen selected from F, Cl, and Br; C 1-6  alkyl, optionally substituted with at least one substituent, selected from hydroxy, halogen, C 1-3  (halo)alkoxy, and C 3-6  (halo)cycloalkyl; C 3-6  cycloalkyl, optionally substituted with at least one substituent, selected from hydroxy, halogen, C 1-3  (halo)alkyl and C 1-3  (halo)alkoxy; C 1-6  alkoxy, optionally substituted with at least one substituent, selected from hydroxy, halogen, C 1-3  (halo)alkoxy and C 3-6  (halo)cycloalkyl; —O—C 3-6  cycloalkyl, optionally substituted with at least one substituent, selected from hydroxy, halogen, C 1-3  (halo)alkyl and C 1-3  (halo)alkoxy; —S—C 1-3  alkyl, optionally substituted with at least one halogen atom; —SO 2 —C 1-3  alkyl, optionally substituted with at least one halogen atom; and —SF 5 ; or 
 R 1  and R 2  together form a 5 to 7 member carbocycle, optionally substituted with at least one substituent, selected from hydroxy, halogen, C 1-3  (halo)alkyl and C 1-3  (halo)alkoxy; and a 5 to 7 member heterocycle containing one to three heteroatoms which can be O, S or N, optionally substituted with at least one substituent, selected from hydroxy, halogen, C 1-3  (halo)alkyl and C 1-3  (halo)alkoxy; 
 R 3  and R 4  are each independently selected from hydrogen; halogen; C 1-5  (halo)alkyl, optionally substituted with at least one halogen atom, provided that at least one of R 3  and R 4  is hydrogen; 
 R 5  and R 6  are each independently selected from hydrogen; halogen; amino; C 1-5  alkyl, optionally substituted with at least one substituent, selected from halogen, hydroxy, C 1-3  (halo)alkoxy and C 3-6  (halo)cycloalkyl; C 1-5  alkoxy, optionally substituted with at least one substituent, selected from hydroxy, halogen, C 1-3  (halo)alkoxy, and C 3-6  (halo)cycloalkyl, and C 3-6  cycloalkyl, optionally substituted with at least one substituent, selected from hydroxy, halogen, C 1-3  (halo)alkyl and C 1-3  (halo)alkoxy; and 
 R 7  is hydrogen; C 1-5  alkyl, optionally substituted with at least one substituent, selected from halogen, hydroxy, C 1-3  (halo)alkoxy and C 3-6  (halo)cycloalkyl; or C 3-6  cycloalkyl, optionally substituted with at least one substituent, selected from hydroxy, halogen, C 1-3  (halo)alkyl and C 1-3  (halo)alkoxy, 
 wherein at least one of at least one of R 1  and R 2  is not hydrogen. 
 
     
     
       2. The compound of  claim 1 , wherein n is 1. 
     
     
       3. The compound of  claim 1 , wherein at least one of R 1  and R 2  is not hydrogen. 
     
     
       4. The compound of  claim 2 , wherein at least one of R 1  and R 2  is not hydrogen. 
     
     
       5. The compound of  claim 1 , wherein at least one of R 1  and R 2  is selected from F, Cl, Br, C 1-4  (halo)alkyl, C 3-6  (halo)cycloalkyl, C 1-3  (halo)alkoxy, C 1-3  (halo)alkoxy-C 1-3  (halo)alkyl, C 3-6  (halo)cycloalkyl-C 1-3  (halo)alkyl, and C 3-6  (halo)cycloalkyl-C 1-3  (halo)alkoxy and wherein R 3  and R 4  are each independently selected from hydrogen, F, Cl, Br, and C 1-3  (halo)alkyl, with the proviso that at least one of R 3  and R 4  is hydrogen. 
     
     
       6. The compound of  claim 1 , wherein R 3  and R 4  are each independently selected from hydrogen, F, Cl, Br, and C 1-3  (halo)alkyl, with the proviso that at least one of R 3  and R 4  is hydrogen. 
     
     
       7. The compound of  claim 1 , wherein:
 Het is selected from 
 
       
         
           
           
               
               
           
         
       
       wherein:
 R 5  and R 6  are each independently selected from hydrogen, F, Cl, amino, C 1-3  alkyl, optionally substituted with at least one substituent selected from halogen, hydroxy, and C 1-3  (halo)alkoxy, C 1-3  (halo)alkoxy, C 3-6  (halo)cycloalkyl, and C 3-6  (halo)cycloalkyl-C 1-3 (halo)alkyl; and 
 R 7  is hydrogen, C 1-3  alkyl, optionally substituted with at least one substituent, selected from halogen, hydroxy, C 1-3  (halo)alkoxy and C 3-6  (halo)cycloalkyl, or C 1-6  cycloalkyl, optionally substituted with at least one substituent, selected from hydroxy, halogen, C 1-3  (halo)alkyl and C 1-3  (halo)alkoxy. 
 
     
     
       8. The compound of  claim 1 , wherein:
 n is 1, 
 R 1  and R 2  are each independently selected from F, Cl, C 1-2  (halo)alkyl, and C 1-2  (halo)alkoxy; 
 Het is selected from 
 
       
         
           
           
               
               
           
         
         R 3  and R 4  are each independently selected from hydrogen, F, and Cl, with the proviso that at least one of R 3  and R 4  is hydrogen; 
         R 5  and R 6  are each independently selected from hydrogen, C 1-3  (halo)alkyl, C 3-6  (halo)cycloalkyl, C 3-6  (halo)cycloalkyl, and C 3-6  (halo)cycloalkyl-C 1-3 (halo)alkyl; and 
         R 7  is hydrogen, C 1-3  alkyl, optionally substituted with at least one substituent, selected from halogen, hydroxy, C 1-3  (halo)alkoxy and C 3-6  (halo)cycloalkyl, C 3-5  cycloalkyl, optionally substituted with at least one substituent, selected from hydroxy, halogen, C 1-3  (halo)alkyl and C 1-3  (halo)alkoxy. 
       
     
     
       9. The A compound of  claim 1  selected from the group consisting of:
 4-[2-[4-[4-chloro-3-(difluoromethoxy)phenyl]pyrazol-1-yl]ethyl]-3,5-dimethyl-1H-pyrazole, 
 3-[[4-[4-chloro-3-(difluoromethoxy)phenyl]pyrazol-1-yl]methyl]-1-methylpyrazole, 
 5-[[4-[4-chloro-3-(difluoromethoxy)phenyl]pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 4-[4-chloro-3-(difluoromethoxy)phenyl]-1-[(1-methylpyrazol-4-yl)methyl]pyrazole, 
 4-[4-chloro-3-(difluoromethoxy)phenyl]-1-[(2-methylpyrazol-3-yl)methyl]pyrazole, 
 4-[4-chloro-3-(difluoromethoxy)phenyl]-1-(1H-pyrazol-3-ylmethyl)-pyrazole, 
 4-[4-chloro-3-(difluoromethoxy)phenyl]-1-(1H-pyrazol-4-ylmethyl)pyrazole, 
 3-[[4-[4-chloro-3-(difluoromethoxy)phenyl]pyrazol-1-yl]methyl]-1-ethylpyrazole, 
 4-[4-chloro-3-(difluoromethoxy)phenyl]-1-[2-(1H-pyrazol-4-yl)ethyl]pyrazole, 
 4-[4-chloro-3-(difluoromethoxy)phenyl]-1-[2-(1-ethylpyrazol-4-yl)ethyl]pyrazole, 
 3-[[4-[4-chloro-3-(difluoromethoxy)phenyl]pyrazol-1-yl]methyl]-1-(1-ethylpropyl)-pyrazole, 
 3-[[4-[4-chloro-3-(difluoromethoxy)phenyl]pyrazol-1-yl]methyl]-1-cyclopentyl-pyrazole, 
 4-[4-chloro-3-(difluoromethoxy)phenyl]-1-[(3-methyl-1H-pyrazol-5-yl)methyl]pyrazole, 
 3-[[4-[4-chloro-3-(difluoromethoxy)phenyl]pyrazol-1-yl]methyl]-5-ethyl-1H-pyrazole, 
 3-[[4-[4-chloro-3-(difluoromethoxy)phenyl]pyrazol-1-yl]methyl]-5-propyl-1H-pyrazole, 
 4-[4-chloro-3-(difluoromethoxy)phenyl]-1-[(5-methyl-1H-pyrazol-4-yl)methyl]pyrazole, 
 4-[4-chloro-3-(difluoromethoxy)phenyl]-1-[(5-ethyl-1H-pyrazol-4-yl)methyl]pyrazole, 
 4-[3-(difluoromethoxy)-4-fluoro-phenyl]-1-(1H-pyrazol-3-ylmethyl)-pyrazole, 
 4-[3-(difluoromethoxy)-4-fluoro-phenyl]-1-[(1methylpyrazol-4-yl)methyl]pyrazole, 
 4-[3-chloro-5-(difluoromethoxy)phenyl]-1-(1H-pyrazol-3-ylmethyl)-pyrazole, 
 1,3-dimethyl-5-[[4-[3-(trifluoromethoxy)phenyl]pyrazol-1-yl]methyl]pyrazole, 
 1-methyl-3-[[4-[3-(trifluoromethoxy)phenyl]pyrazol-1-yl]methyl]pyrazole, 
 3-[[4-[4-chloro-3-(difluoromethyl)phenyl]pyrazol-1-yl]methyl]-1-methyl-pyrazole, 
 5-[[4-[4-chloro-3-(difluoromethyl)phenyl]pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 4-[4-chloro-3-(difluoromethyl)phenyl]-1-(1H-pyrazol-3-ylmethyl)-pyrazole, 
 4-[2-[4-[4-chloro-3-(difluoromethyl)phenyl]pyrazol-1-yl]ethyl]-3,5-dimethyl-1H-pyrazole, 
 4-[3-chloro-5-(difluoromethyl)phenyl]-1-(1H-pyrazol-3-ylmethyl)-pyrazole, 
 5-[[4-[4-chloro-3-(trifluoromethyl)phenyl]pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 3-[[4-[4-chloro-3-(trifluoromethyl)phenyl]pyrazol-1-yl]methyl]-1-methyl-pyrazole, 
 3-[[4-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazol-1-yl]methyl]-1-methyl-pyrazole, 
 5-[[4-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 4-[3-(difluoromethyl)-4-fluoro-phenyl]-1-[(1-methylpyrazol-4-yl)methyl]pyrazole, 
 4-[3-(difluoromethyl)-4-fluoro-phenyl]-1-[(2-methylpyrazol-3-yl)methyl]pyrazole, 
 4-[3-(difluoromethyl)-4-fluoro-phenyl]-1-(1H-pyrazol-3-ylmethyl)pyrazole, 
 4-[2-[4-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazol-1-yl]ethyl]-3,5-dimethyl-1H-pyrazole, 
 4-[3-(difluoromethyl)-4-fluoro-phenyl]-1-[2-(1H-pyrazol-4-yl)ethyl]pyrazole, 
 3-[[4-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazol-1-yl]methyl]-1-ethyl-pyrazole, 
 4-[3-(difluoromethyl)-4-fluoro-phenyl]-1-[(3-methyl-1H-pyrazol-5-yl)methyl]pyrazole, 
 3-[[4-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazol-1-yl]methyl]-5-ethyl-1H-pyrazole, 
 3-[[4-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazol-1-yl]methyl]-5-propyl-1H-pyrazole, 
 4-[3-(difluoromethyl)-4-fluoro-phenyl]-1-[(5-methyl-1H-pyrazol-4-yl)methyl]pyrazole, 
 4-[3-(difluoromethyl)-4-fluoro-phenyl]-1-[(5-ethyl-1H-pyrazol-4-yl)methyl]pyrazole, 
 4-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]-1-(1H-pyrazol-3-ylmethyl)pyrazole, 
 4-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]-1-[(1-methylpyrazol-4-yl)methyl]pyrazole, 
 4-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]-1-[(5-ethyl-1H-pyrazol-4-yl)methyl]pyrazole, 
 4-[3-(difluoromethyl)-5-fluoro-phenyl]-1-[2-(1H-pyrazol-3-ylmethyl]pyrazole, 
 1,3-dimethyl-5-[[4-[3-(trifluoromethyl)phenyl]pyrazol-1-yl]methyl]pyrazole, 
 1-methyl-3-[[4-[3-(trifluoromethyl)phenyl]pyrazol-1-yl]methyl]pyrazole, 
 1-methyl-3-[[4-[4-(trifluoromethyl)phenyl]pyrazol-1-yl]methyl]pyrazole, 
 1,3-dimethyl-5-[[4-[4-(trifluoromethyl)phenyl]pyrazol-1-yl]methyl]pyrazole, 
 5-[[4-(3-fluoro-4-methyl-phenyl)pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 5-[[4-(3-fluoro-4-methyl-phenyl)pyrazol-1-yl]methyl]-1-methyl-pyrazole, 
 5-[[4-(4-fluoro-3-methyl-phenyl)pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 3-[[4-(4-fluoro-3-methyl-phenyl)pyrazol-yl]methyl]-1-methyl-pyrazole, 
 4-(4-fluoro-3-methyl-phenyl)-1-(1H-pyrazol-3-ylmethyl)-pyrazole, 
 5-[[4-(4-chloro-3-methyl-phenyl)pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 3-[[4-(4-chloro-3-methyl-phenyl)pyrazol-1-yl]methyl]-1-methyl-pyrazole, 
 3-[[4-(4-chloro-3-fluoro-phenyl)pyrazol-1-yl]methyl]-1-methyl-pyrazole, 
 5-[[4-(4-chloro-3-fluoro-phenyl)pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 3-[[4-(3-chloro-4-fluoro-phenyl)pyrazol-1-yl]methyl]-1-methyl-pyrazole, 
 5-[[4-(3-chloro-4-fluoro-phenyl)pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 3-[[4-(3,4-dichlorophenyl)pyrazol-1-yl]methyl]-1-methyl-pyrazole, 
 5-[[4-(3,4-dichlorophenyl)pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 5-[[4-(2,4-dichlorophenyl)pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 3-[[4-(2,4-dichlorophenyl)pyrazol-1-yl]methyl]-1-methyl-pyrazole, 
 3-[[4-(4-fluoro-2-methoxy-phenyl)pyrazol-1-yl]methyl]-1-methyl-pyrazole, 
 5-[[4-(4-fluoro-2-methoxy-phenyl)pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 4-(3-cyclopropylphenyl)-1-(1H-pyrazol-3-ylmethyl)-pyrazole, 
 4-(3-methylsulfonylphenyl)-1-(1H-pyrazol-3-ylmethyl)-pyrazole, 
 1-methyl-4-[[4-(3-methylsulfonylphenyl)pyrazol-1-yl]methyl]-pyrazole, 
 pentafluoro-[3-[1-(1H-pyrazol-3-ylmethyl)pyrazol-4-yl]]phenyl]-sulfane, 
 4-[2-[4-(4-chlorophenyl)-pyrazol-1-yl]ethyl]-3,5-dimethyl-1H-pyrazole, 
 5-[[4-(4-chlorophenyl)-pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 3-[[4-(4-chlorophenyl)-pyrazol-1-yl]methyl]-1-methyl-pyrazole, 
 4-(4-chlorophenyl)-1-[(2-methylpyrazol-3-yl)methyl]pyrazole, 
 4-(4-chlorophenyl)-1-(1H-pyrazol-3-ylmethyl)pyrazole, 
 4-(4-chlorophenyl)-1-[(1-methylpyrazol-4-yl)methyl]pyrazole, 
 3-[[4-(4-bromophenyl)pyrazol-1-yl]methyl]-1-methyl-pyrazole, 
 5-[[4-(4-bromophenyl)pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 5-[[4-(3-bromophenyl)pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 3-[[4-(3-bromophenyl)pyrazol-1-yl]methyl]-1-methyl-pyrazole, 
 5-[[4-(3,5-difluorophenyl)pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 3-[[4-(3,5-difluorophenyl)pyrazol-1-yl]methyl]-1-methyl-pyrazole, 
 1-methyl-3-[(4-phenylpyrazol-1-yl)methyl]pyrazole, 
 1,3-dimethyl-5-[(4-phenylpyrazol-1-yl)methyl]pyrazole, and 
 1-methyl-5-[(4-phenylpyrazol-1-yl)methyl]pyrazole; and 
 pharmaceutically acceptable salt, solvate, polymorph, or N-oxide thereof. 
 
     
     
       10. The compound of  claim 1  selected from the group consisting of:
 4-[[4-(3-difluoromethoxy-4-chloro-phenyl)pyrazol-1-yl]methyl]-3,5-dimethyl-1H-pyrazole, 
 4-[[4-(3-difluoromethyl-4-fluoro-phenyl)pyrazol-1-yl]methyl]-3,5-dimethyl-1H-pyrazole, 
 4-[[4-(3-(1,1-difluoroethyl-4-fluoro-phenyl)pyrazol-1-yl]methyl]-3,5-dimethyl-1H-pyrazole, 
 3-[[4-[3-(difluoromethoxy)-4-fluoro-phenyl]pyrazol-1-yl]methyl]-4-ethyl-1H-pyrazole, 
 3-[[4-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazol-1-yl]methyl]-4-ethyl-1H-pyrazole, 
 3-[[4-(3-(1,1-difluoroethyl)-phenyl)pyrazol-1-yl]methyl]-1H-pyrazole, and 
 3-[[4-(3-(difluoromethoxy)-phenyl)pyrazol-1-yl]methyl]-1H-pyrazole and 
 pharmaceutically acceptable salt, solvate, polymorph, or N-oxide thereof. 
 
     
     
       11. The A compound of  claim 1  selected from the group consisting of:
 4-(4-chloro-3-(difluoromethyl)phenyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-pyrazole, 
 4-(4-chlorophenyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-pyrazole, 
 4-(3,4-dichlorophenyl)-2′-methyl-2′H-1,3′-bipyrazole, 
 4-(3-chloro-4-fluorophenyl)-2′-methyl-2′H-1,3′-bipyrazole, 
 2-((4-(4-chlorophenyl)-1H-pyrazol-1-yl)methyl)imidazo[1,2-a]pyridine, 
 3-(3-(difluoromethyl)-4-fluorophenyl)-1-((5-((4-(3-(difluoromethyl)-4-fluorophenyl)-1H-pyrazol-1-yl)methyl)-1H-pyrazol-3-yl)methyl)-1H-pyrazole, and 
 2-(1-((1-methyl-1H-pyrazol-3-yl)methyl)-1H-pyrazol-4-yl)pyridine; and 
 pharmaceutically acceptable salt, solvate, polymorph, or N-oxide thereof. 
 
     
     
       12. A pharmaceutical composition comprising a therapeutically effective amount of a compound of  claim 1  or pharmaceutically acceptable salt, solvate, polymorph, or N-oxide thereof, and at least one pharmaceutically acceptable excipient. 
     
     
       13. The pharmaceutical composition of  claim 12 , further comprising a second active ingredient. 
     
     
       14. A method of treating a disease, disorder or condition associated with NMDA receptor hyperactivity comprising administering to a patient in need thereof a therapeutically effective amount of a compound of  claim 1 , or a pharmaceutically acceptable salt, solvate, polymorph, or N-oxide thereof. 
     
     
       15. The method of  claim 14 , wherein the disorder, disease or condition is selected from the group consisting of: bipolar disorder, major depressive disorder, and treatment-resistant depression. 
     
     
       16. A method for treating a disease, disorder or condition mediated by GluN2B receptors comprising administering to a patient in need thereof a therapeutically effective amount of a compound of  claim 1 , or a pharmaceutically acceptable salt, solvate, polymorph, or N-oxide thereof. 
     
     
       17. The method of  claim 16 , wherein the disorder, disease or condition is selected from the group consisting of treatment resistant depression and major depressive disorder. 
     
     
       18. A method of treating a disease, disorder or condition in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of  claim 1 , or a pharmaceutically acceptable salt, solvate, polymorph, or N-oxide thereof. 
     
     
       19. The method of  claim 18 , wherein the disease or disorder is a neurologic or psychiatric disorder. 
     
     
       20. The method of  claim 19 , wherein the disease or disorder is selected from the group consisting of a mood disorder; a stress-related disorder and neurodegeneration. 
     
     
       21. The method of  claim 20 , wherein the stress-related disorder is an anxiety disorder. 
     
     
       22. The method of  claim 19  wherein the neurologic disorder is epilepsy. 
     
     
       23. The method of  claim 17 , wherein the disorder, disease or condition is treatment resistant depression. 
     
     
       24. The method of  claim 17 , wherein the disorder, disease or condition is major depressive disorder. 
     
     
       25. The compound of  claim 1  selected from the group consisting of:
 4-[4-Chloro-3-(difluoromethoxy)phenyl]-1-[(1-methylpyrazol-4-yl)methyl]pyrazole; 
 4-[4-Chloro-3-(difluoromethoxy)phenyl]-1-[(2-methylpyrazol-3-yl)methyl]pyrazole; 
 4-[4-Chloro-3-(difluoromethoxy)phenyl]-1-(1H-pyrazol-3-ylmethyl)-pyrazole; 
 4-[4-Chloro-3-(difluoromethoxy)phenyl]-1-(1H-pyrazol-4-ylmethy)pyrazole; 
 4-[4-Chloro-3-(difluoromethoxy)phenyl]-1-[(5-methyl-1H-pyrazol-4-yl)methyl]pyrazole; 
 4-[4-Chloro-3-(difluoromethoxy)phenyl]-1-[(5-ethyl-1H-pyrazol-4-yl)methyl]pyrazole; 
 4-[3-(Difluoromethoxy)-4-fluoro-phenyl]-1-(1H-pyrazol-3-ylmethyl)-pyrazole; 
 4-[4-Chloro-3-(difluoromethyl)phenyl]-1-(1H-pyrazol-3-ylmethyl)pyrazole; 
 4-[3-(Difluoromethyl)-4-fluoro-phenyl]-1-(1H-pyrazol-3-ylmethyl)pyrazole; and 
 4-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]-1-(1H-pyrazol-3-ylmethyl)pyrazole; and 
 pharmaceutically acceptable salt, solvate, polymorph, or N-oxide thereof. 
 
     
     
       26. A method of treating a disorder in a patient comprising administering to a patient in need thereof a compound of  claim 25  wherein the disorder is selected from the group consisting of bipolar disorder, major depressive disorder, and treatment-resistant depression. 
     
     
       27. A method of  claim 26  wherein the disorder is major depressive disorder. 
     
     
       28. A method of treating a disorder in a patient comprising administering to a patient in need thereof a compound of  claim 25  wherein the disorder is epilepsy. 
     
     
       29. A pharmaceutical composition comprising a therapeutically effective amount of a compound selected from the group consisting of:
 4-[2-[4-[4-chloro-3-(difluoromethoxy)phenyl]pyrazol-1-yl]ethyl]-3,5-dimethyl-1H-pyrazole, 
 3-[[4-[4-chloro-3-(difluoromethoxy)phenyl]pyrazol-1-yl]methyl]-1-methylpyrazole, 
 5-[[4-[4-chloro-3-(difluoromethoxy)phenyl]pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 4-[4-chloro-3-(difluoromethoxy)phenyl]-1-[(1-methylpyrazol-4-yl)methyl]pyrazole, 
 4-[4-chloro-3-(difluoromethoxy)phenyl]-1-[(2-methylpyrazol-3-yl)methyl]pyrazole, 
 4-[4-chloro-3-(difluoromethoxy)phenyl]-1-(1H-pyrazol-3-ylmethyl)-pyrazole, 
 4-[4-chloro-3-(difluoromethoxy)phenyl]-1-(1H-pyrazol-4-ylmethyl)pyrazole, 
 3-[[4-[4-chloro-3-(difluoromethoxy)phenyl]pyrazol-1-yl]methyl]-1-ethylpyrazole, 
 4-[4-chloro-3-(difluoromethoxy)phenyl]-1-[2-(1H-pyrazol-4-yl)ethyl]pyrazole, 
 4-[4-chloro-3-(difluoromethoxy)phenyl]-1-[2-(1-ethylpyrazol-4-yl)ethyl]pyrazole, 
 3-[[4-[4-chloro-3-(difluoromethoxy)phenyl]pyrazol-1-yl]methyl]-1-(1-ethylpropyl)-pyrazole, 
 3-[[4-[4-chloro-3-(difluoromethoxy)phenyl]pyrazol-1-yl]methyl]-1-cyclopentyl-pyrazole, 
 4-[4-chloro-3-(difluoromethoxy)phenyl]-1-[(3-methyl-1H-pyrazol-5-yl)methyl]pyrazole, 
 3-[[4-[4-chloro-3-(difluoromethoxy)phenyl]pyrazol-1-yl]methyl]-5-ethyl-1H-pyrazole, 
 3-[[4-[4-chloro-3-(difluoromethoxy)phenyl]pyrazol-1-yl]methyl]-5-propyl-1H-pyrazole, 
 4-[4-chloro-3-(difluoromethoxy)phenyl]-1-[(5-methyl-1H-pyrazol-4-yl)methyl]pyrazole, 
 4-[4-chloro-3-(difluoromethoxy)phenyl]-1-[(5-ethyl-1H-pyrazol-4-yl)methyl]pyrazole, 
 4-[3-(difluoromethoxy)-4-fluoro-phenyl]-1-(1H-pyrazol-3-ylmethyl)-pyrazole, 
 4-[3-(difluoromethoxy)-4-fluoro-phenyl]-1-[(1methylpyrazol-4-yl)methyl]pyrazole, 
 4-[3-chloro-5-(difluoromethoxy)phenyl]-1-(1H-pyrazol-3-ylmethyl)-pyrazole, 
 1,3-dimethyl-5-[[4-[3-(trifluoromethoxy)phenyl]pyrazol-1-yl]methyl]pyrazole, 
 1-methyl-3-[[4-[3-(trifluoromethoxy)phenyl]pyrazol-1-yl]methyl]pyrazole, 
 3-[[4-[4-chloro-3-(difluoromethyl)phenyl]pyrazol-1-yl]methyl]-1-methyl-pyrazole, 
 5-[[4-[4-chloro-3-(difluoromethyl)phenyl]pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 4-[4-chloro-3-(difluoromethyl)phenyl]-1-(1H-pyrazol-3-ylmethyl)-pyrazole, 
 4-[2-[4-[4-chloro-3-(difluoromethyl)phenyl]pyrazol-1-yl]ethyl]-3,5-dimethyl-1H-pyrazole, 
 4-[3-chloro-5-(difluoromethyl)phenyl]-1-(1H-pyrazol-3-ylmethyl)-pyrazole, 
 5-[[4-[4-chloro-3-(trifluoromethyl)phenyl]pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 3-[[4-[4-chloro-3-(trifluoromethyl)phenyl]pyrazol-1-yl]methyl]-1-methyl-pyrazole, 
 3-[[4-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazol-1-yl]methyl]-1-methyl-pyrazole, 
 5-[[4-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 4-[3-(difluoromethyl)-4-fluoro-phenyl]-1-[(1-methylpyrazol-4-yl)methyl]pyrazole, 
 4-[3-(difluoromethyl)-4-fluoro-phenyl]-1-[(2-methylpyrazol-3-yl)methyl]pyrazole, 
 4-[3-(difluoromethyl)-4-fluoro-phenyl]-1-(1H-pyrazol-3-ylmethyl)pyrazole, 
 4-[2-[4-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazol-1-yl]ethyl]-3,5-dimethyl-1H-pyrazole, 
 4-[3-(difluoromethyl)-4-fluoro-phenyl]-1-[2-(1H-pyrazol-4-yl)ethyl]pyrazole, 
 3-[[4-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazol-1-yl]methyl]-1-ethyl-pyrazole, 
 4-[3-(difluoromethyl)-4-fluoro-phenyl]-1-[(3-methyl-1H-pyrazol-5-yl)methyl]pyrazole, 
 3-[[4-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazol-1-yl]methyl]-5-ethyl-1H-pyrazole, 
 3-[[4-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazol-1-yl]methyl]-5-propyl-1H-pyrazole, 
 4-[3-(difluoromethyl)-4-fluoro-phenyl]-1-[(5-methyl-1H-pyrazol-4-yl)methyl]pyrazole, 
 4-[3-(difluoromethyl)-4-fluoro-phenyl]-1-[(5-ethyl-1H-pyrazol-4-yl)methyl]pyrazole, 
 4-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]-1-(1H-pyrazol-3-ylmethyl)pyrazole, 
 4-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]-1-[(1-methylpyrazol-4-yl)methyl]pyrazole, 
 4-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]-1-[(5-ethyl-1H-pyrazol-4-yl)methyl]pyrazole, 
 4-[3-(difluoromethyl)-5-fluoro-phenyl]-1-[2-(1H-pyrazol-3-ylmethyl]pyrazole, 
 1,3-dimethyl-5-[[4-[3-(trifluoromethyl)phenyl]pyrazol-1-yl]methyl]pyrazole, 
 1-methyl-3-[[4-[3-(trifluoromethyl)phenyl]pyrazol-1-yl]methyl]pyrazole, 
 1-methyl-3-[[4-[4-(trifluoromethyl)phenyl]pyrazol-1-yl]methyl]pyrazole, 
 1,3-dimethyl-5-[[4-[4-(trifluoromethyl)phenyl]pyrazol-1-yl]methyl]pyrazole, 
 5-[[4-(3-fluoro-4-methyl-phenyl)pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 5-[[4-(3-fluoro-4-methyl-phenyl)pyrazol-1-yl]methyl]-1-methyl-pyrazole, 
 5-[[4-(4-fluoro-3-methyl-phenyl)pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 3-[[4-(4-fluoro-3-methyl-phenyl)pyrazol-yl]methyl]-1-methyl-pyrazole, 
 4-(4-fluoro-3-methyl-phenyl)-1-(1H-pyrazol-3-ylmethyl)-pyrazole, 
 5-[[4-(4-chloro-3-methyl-phenyl)pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 3-[[4-(4-chloro-3-methyl-phenyl)pyrazol-1-yl]methyl]-1-methyl-pyrazole, 
 3-[[4-(4-chloro-3-fluoro-phenyl)pyrazol-1-yl]methyl]-1-methyl-pyrazole, 
 5-[[4-(4-chloro-3-fluoro-phenyl)pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 3-[[4-(3-chloro-4-fluoro-phenyl)pyrazol-1-yl]methyl]-1-methyl-pyrazole, 
 5-[[4-(3-chloro-4-fluoro-phenyl)pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 3-[[4-(3,4-dichlorophenyl)pyrazol-1-yl]methyl]-1-methyl-pyrazole, 
 5-[[4-(3,4-dichlorophenyl)pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 5-[[4-(2,4-dichlorophenyl)pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 3-[[4-(2,4-dichlorophenyl)pyrazol-1-yl]methyl]-1-methyl-pyrazole, 
 3-[[4-(4-fluoro-2-methoxy-phenyl)pyrazol-1-yl]methyl]-1-methyl-pyrazole, 
 5-[[4-(4-fluoro-2-methoxy-phenyl)pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 4-(3-cyclopropylphenyl)-1-(1H-pyrazol-3-ylmethyl)-pyrazole, 
 4-(3-methylsulfonylphenyl)-1-(1H-pyrazol-3-ylmethyl)-pyrazole, 
 1-methyl-4-[[4-(3-methylsulfonylphenyl)pyrazol-1-yl]methyl]-pyrazole, 
 pentafluoro-[3-[1-(1H-pyrazol-3-ylmethyl)pyrazol-4-yl]]phenyl]-sulfane, 
 4-[2-[4-(4-chlorophenyl)-pyrazol-1-yl]ethyl]-3,5-dimethyl-1H-pyrazole, 
 5-[[4-(4-chlorophenyl)-pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 3-[[4-(4-chlorophenyl)-pyrazol-1-yl]methyl]-1-methyl-pyrazole, 
 4-(4-chlorophenyl)-1-[(2-methylpyrazol-3-yl)methyl]pyrazole, 
 4-(4-chlorophenyl)-1-(1H-pyrazol-3-ylmethyl)pyrazole, 
 4-(4-chlorophenyl)-1-[(1-methylpyrazol-4-yl)methyl]pyrazole, 
 3-[[4-(4-bromophenyl)pyrazol-1-yl]methyl]-1-methyl-pyrazole, 
 5-[[4-(4-bromophenyl)pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 5-[[4-(3-bromophenyl)pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 3-[[4-(3-bromophenyl)pyrazol-1-yl]methyl]-1-methyl-pyrazole, 
 5-[[4-(3,5-difluorophenyl)pyrazol-1-yl]methyl]-1,3-dimethyl-pyrazole, 
 3-[[4-(3,5-difluorophenyl)pyrazol-1-yl]methyl]-1-methyl-pyrazole, 
 1-methyl-3-[(4-phenylpyrazol-1-yl)methyl]pyrazole, 
 1,3-dimethyl-5-[(4-phenylpyrazol-1-yl)methyl]pyrazole, and 
 1-methyl-5-[(4-phenylpyrazol-1-yl)methyl]pyrazole; and 
 
       and pharmaceutically acceptable salt, solvate, polymorph, or N-oxide thereof, and at least one pharmaceutically acceptable excipient. 
     
     
       30. A pharmaceutical composition comprising a therapeutically effective amount of a compound selected from the group consisting of:
 4-[[4-(3-Difluoromethoxy-4-chloro-phenyl)pyrazol-1-yl]methyl]-3,5-dimethyl-1H-pyrazole, 
 4-[[4-(3-Difluoromethyl-4-fluoro-phenyl)pyrazol-1-yl]methyl]-3,5-dimethyl-1H-pyrazole, 
 4-[[4-(3-(1,1-Difluoroethyl-4-fluoro-phenyl)pyrazol-1-yl]methyl]-3,5-dimethyl-1H-pyrazole, 
 3-[[4-[3-(Difluoromethoxy)-4-fluoro-phenyl]pyrazol-1-yl]methyl]-4-ethyl-1H-pyrazole, 
 3-[[4-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazol-1-yl]methyl]-4-ethyl-1H-pyrazole, 
 3-[[4-(3-(1,1-Difluoroethyl)-phenyl)pyrazol-1-yl]methyl]-1H-pyrazole, and 
 
       3-[[4-(3-(Difluoromethoxy)-phenyl)pyrazol-1-yl]methyl]-1H-pyrazole; 
       and pharmaceutically acceptable salt, solvate, polymorph, or N-oxide thereof, and at least one pharmaceutically acceptable excipient. 
     
     
       31. A pharmaceutical composition comprising a therapeutically effective amount of a compound selected from the group consisting of:
 4-(4-Chloro-3-(difluoromethyl)phenyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-pyrazole, 
 4-(4-Chlorophenyl)-1-(1-ethyl-1H-imidazol-5-yl)methyl)-1H-pyrazole, 
 4-(3,4-Dichlorophenyl)-2′-methyl-2′H-1,3′-bipyrazole, 
 4-(3-Chloro-4-fluorophenyl)-2′-methyl-2′H-1,3′-bipyrazole, 
 2-((4-(4-Chlorophenyl)-1H-pyrazol-1-yl)methyl)imidazo[1,2-a]pyridine, 
 3-(3-(Difluoromethyl)-4-fluorophenyl)-1-((5-((4-(3-(difluoromethyl)-4-fluorophenyl)-1H-pyrazol-1-yl)methyl)-1H-pyrazol-3-yl)methyl)-1H-pyrazole, and 
 2-(1-((1-Methyl-1H-pyrazol-3-yl)methyl)-1H-pyrazol-4-yl)pyridine; 
 
       and pharmaceutically acceptable salt, solvate, polymorph, or N-oxide thereof, and at least one pharmaceutically acceptable excipient. 
     
     
       32. A pharmaceutical composition comprising a therapeutically effective amount of a compound selected from the group consisting of:
 4-[4-Chloro-3-(difluoromethoxy)phenyl]-1-[(1-methylpyrazol-4-yl)methyl]pyrazole; 
 4-[4-Chloro-3-(difluoromethoxy)phenyl]-1-[(2-methylpyrazol-3-yl)methyl]pyrazole; 
 4-[4-Chloro-3-(difluoromethoxy)phenyl]-1-(1H-pyrazol-3-ylmethyl)-pyrazole; 
 4-[4-Chloro-3-(difluoromethoxy)phenyl]-1-(1H-pyrazol-4-ylmethyl)pyrazole; 
 4-[4-Chloro-3-(difluoromethoxy)phenyl]-1-[(5-methyl-1H-pyrazol-4-yl)methyl]pyrazole; 
 4-[4-Chloro-3-(difluoromethoxy)phenyl]-1-[(5-ethyl-1H-pyrazol-4-yl)methyl]pyrazole; 
 4-[3-(Difluoromethoxy)-4-fluoro-phenyl]-1-(1H-pyrazol-3-ylmethyl)-pyrazole; 
 4-[4-Chloro-3-(difluoromethyl)phenyl]-1-(1H-pyrazol-3-ylmethyl)pyrazole; 
 4-[3-(Difluoromethyl)-4-fluoro-phenyl]-1-(1H-pyrazol-3-ylmethyl)pyrazole; and 
 4-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]-1-(1H-pyrazol-3-ylmethyl)pyrazole; 
 
       and pharmaceutically acceptable salt, solvate, polymorph, or N-oxide thereof, and at least one pharmaceutically acceptable excipient.
Cited by (0)

No later patents cite this yet.
References (0)

No backward citations on record.